Gilead stock is still recovering from the decline of its once-booming hepatitis C business - that's what happens when you cure most of your customers.
But over the past year, with a new CEO, this biotech has taken steps that will return it to growth.
Wall Street doesn't realize it yet, but GILD is a stock to buy...
Gilead stock is still recovering from the decline of its once-booming hepatitis C business - that's what happens when you cure most of your customers.
But over the past year, with a new CEO, this biotech has taken steps that will return it to growth.
Wall Street doesn't realize it yet, but GILD is a stock to buy...
The Gilead stock price has seen a massive downturn lately.
Since last month, GILD stock has fallen nearly 20% to $82 a share.
But we see shares of the biotech giant heading sharply higher by next year for two big reasons...
Our Gilead stock price prediction shows gains ahead, even after Gilead Sciences Inc. (Nasdaq: GILD) shares have fallen more than 7% since the beginning of August.
You see, the Gilead stock price recently got caught up in a sell-off of biotech stocks as regulators continue to investigate companies for drug price gouging.
But the stock price's drop has only made GILD stock more attractive
Gilead Sciences Inc. (Nasdaq: GILD) is facing criticism again this week for its highly priced Hepatitis C drug Sovaldi. The drug costs $1,000 per pill.
According to The Wall Street Journal, many states have restricted access to the drug, leaving some patients unable to afford the treatment.
Our 2015 stock picks show us two trends.
Precious metals are still surging. And now, biotech stocks are coming into 2015 hot.
Take a look at these exciting developments for our top stocks in 2015...
Today I want to reintroduce you to a biotech stock that Wall Street has been pricing as though it were dead money.
This biotech company recently filed a stellar earnings report. But those earnings were slightly off analyst expectations, and the share price dipped.
Since April 11, Gilead Sciences (Nasdaq: GILD) has scored peak gains of a 74.2% - or more than 175% annualized gains.
Some investors don't want to risk it all during a sell-off - but they still want to take advantage of the growth biotech stocks offer.
Gilead Sciences Inc. (Nasdaq: GILD) stock hit a 52-week high of $92.97 this morning (Thursday) after the company crushed earnings estimates last night. At that price, the stock was up 3% from yesterday's closing price.
Money Morning’s Defense and Tech Specialist Michael Robinson has been high on GILD stock for some time, and yesterday’s huge earnings beat comes as no surprise to Money Morning readers.
Here’s why this hot biotech stock is just getting started.
